TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05845541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Supported Meditation and Biofeedback
Description: Patient's in the treatment arm will participate in technology based meditation using the iom2 and Journeys app at least 3 times/ week. This will involve placing a probe on their ear attached to the iom2 and following the guidance provided by the Journeys App.~During and following each session, participants will be shown their average heart rate variability (HRV) score, average HRV, and time spent on the session. Patients will be able to review sessions and keep track of their progress. Participants in the intervention arm will be asked to complete the outcome measures prior to their hospital discharge. As well, an informal discussion about the patient's experience using technology based meditation will be transcribed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Patients at St. John's Rehab undergoing rehabilitation are supported by an interprofessional team - including physiatrists, nurses, occupational therapists, speech language pathologists, physical therapists, social workers and psychiatrists. During their inpatient stay, patients receive a wide range of rehabilitation services aimed at addressing their physical, emotional and cognitive care needs. Length of stay for inpatient services ranges between 2 to 12 weeks.
Study: NCT05061381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A Lust for Life Schools Programme
Description: A Lust for Life is a universal school-based multi-component programme whose target is to build well-being and emotional resilience in children. The programme was informed by evidence-based psychological approaches including mindfulness, cognitive behaviour therapy and positive psychology. It is delivered in six weekly lessons by the childrens' school teacher and involves classroom discussions, videos, classroom activities and homework assignments.
Study: NCT05812430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib+TQB2450+nab-paclitaxel+cisplatin
Description: Anlotinib: 10mg, po, d1\~14, q3w, until disease progression or unacceptable toxicity.~TQB2450: 1200mg, ivgtt, d1, q3w, until disease progression or unacceptable toxicity.~nab-paclitaxel: 200mg/㎡, ivgtt, d1, q3w, 6 cycles. cisplatin: 60mg/㎡, ivgtt, d1, q3w, 6 cycles.
Study: NCT05011578

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiographic assessment
Description: Radiographic assessment after at least 10 years after radiocapitellar surgical treatment
Study: NCT05650970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine therapy
Description: Routine treatment program including massage, ice and activity training applied to hand thumb osteoarthritis patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: radial nerve mobilization exercise
Description: Radial nerve mobilization exercise in addition to the routine treatment program applied to patients with hand thumb osteoarthritis
Study: NCT05764135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI-Lynx Mobile Application
Description: . The SCI-Lynx application will enable people to find others with the same chronic condition who have similar exercise interests and goals. Individuals can make social connections, set, and track their exercise goals and support one another in their physical activities. It provides content customized for each condition to encourage participant's belief in the benefits of exercise and improve their self-efficacy for exercise through tracking of their own progress. An additional feature of SCI-Lynx is the ability to direct messages to other individuals or create subgroups within their network providing a further social support for individuals with SCI.
Study: NCT04993469

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Semmes-Weinstein monofilament testing and questionnaires
Description: Semmes-Weinstein test for the assessment of genital sensation Battery of questionnaires assessing sexual function, voiding function, quality of life and patient satisfaction
Study: NCT05918276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib and BG
Description: Drug: Orelabrutinib Orelabrutinib 200mg, po, qd，C2-C7. Twenty-eight days for a cycle.~Drug: BG Bendamustin 70mg/m2, IV, d2\&d3 inC1, and then d1\&d2 inC2-6.Twenty-eight days for a cycle.~Obintuzumab 100mg IV, d1, 900mg d2, 1000mg d8\&d15 in C1, and then 1000mg/m2 IV, d1 in C2-6. Twenty-eight days for a cycle.
Study: NCT05251675

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Led Professional Coaching
Description: This is a one-on-one intervention between a physician coach and an individual physician. This is meant to help coaches attain valued professional or personal development.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Physician Led Professional Coaching
Description: This intervention will include professional one-on-one professional coaching delayed from the active comparator group.
Study: NCT06051110

Intervention type: DEVICE
Group type: OTHER
Intervention: Combined risk score
Description: Prehospital risk stratification by the use of a combined clinical risk score including POC-troponin

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Prehospital risk stratification by EMS protocols

Intervention type: DEVICE
Group type: OTHER
Intervention: point-of-care troponin
Description: Prehospital risk stratification by the use of a POC-troponin
Study: NCT05089747

Intervention type: BIOLOGICAL
Intervention: Blood sampling for biomarker analysis (microRNA, circulating DNA…)
Description: From one to four blood samplings: at diagnosis, after the first cycle of treatment, end of treatment, progressive disease (or end of study).
Study: NCT05831137

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: shorter cryoanalgesia
Description: duration time of cryoanalgesia
Study: NCT06114849

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment-as-usual will follow the existing RallyPoint procedures for concerning posts on the site. In the current procedures, a RallyPoint staff member sends a supportive message to the member containing resource information on the Veteran's Crisis line, 911, and connecting with a therapist. This information is typically sent within 24 hrs of seeing a concerning post. Participants in both the control and intervention conditions will receive treatment-as-usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Treatment-as-usual will follow the existing RallyPoint procedures for concerning posts on the site. In the current procedures, a RallyPoint staff member sends a supportive message to the member containing resource information on the Veteran's Crisis line, 911, and connecting with a therapist. This information is typically sent within 24 hrs of seeing a concerning post. Participants in both the control and intervention conditions will receive treatment-as-usual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Barrier Reduction Intervention
Description: After a post is identified in real-time by the risk algorithm, participants will be shown a pop-up message offering information on mental health resources (e.g., crisis line). Participants will be asked about their likelihood of using these resources. For participants who indicate they are not likely to use these resources, they will then be presented with a list of common barriers to help-seeking, drawing from research in this area (e.g., Treatment is too expensive or I'm concerned about the police or paramedics getting involved.). Participants will be asked to click on any reason that resonates with them. When they click on a particular reason, they will then be presented with psychoeducational information to allay their concerns and encourage professional help-seeking.
Study: NCT05157945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALTO-300 PO Tablet
Description: One tablet daily
Study: NCT04879342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VIP Program
Description: This intervention will engage the participants with psychoeducational material once a week. This material will include didactic instruction as well as participant engagement in developmentally appropriate activities.
Study: NCT05459155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synapse medicine platform
Description: Intervention is the Synapse medicine platform for inpatient pharmacists. This software analyzes drug-related risks based on each patient's clinical characteristics
Study: NCT06330935

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: 30 patients will be randomized to A arm and 30 patients to B arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: 30 patients will be randomized to A arm and 30 patients to B arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 30 patients will be randomized this arm C
Study: NCT05163223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AST-301(pNGVL3-hICD)
Description: Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuGM-CSF
Description: Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rhuGM-CSF
Description: Q3W, 3 cycles, Plus a booster at 24weeks post the third vaccination, Intradermal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Q3W, 3 cycles, Plus a booster at 24 weeks post the third vaccination, Intradermal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Q3W; IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Q3W; IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: On days 1-14 (Q3W), BID ; Oral administration,
Study: NCT04390308

Intervention type: PROCEDURE
Intervention: Ovarian puncture
Description: Egg collection

Intervention type: OTHER
Intervention: Hormonal blood Test
Description: AMH (ng/ml), FSH (IU/mL), E2(pg/mL), P4(ng/mL), LH (IU/mL)

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal ultrasound
Description: Doppler of arteria ovarica. Resistance index
Study: NCT05963932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986419 DR Capsule
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986419 IR Tablet
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986419 IR Tablet
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986419 IR Tablet
Description: Specified dose on specified days
Study: NCT06385327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-5366
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-5366
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-5366
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-5366
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-5366
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-5366 Placebo
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-5366 Placebo
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-5366 Placebo
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABI-5366 Placebo
Description: Once daily tablet dosing (SAD) or weekly or monthly tablet dosing over 29 days (MAD)
Study: NCT05765669

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous screw fixation
Description: Surgical intervention in the form of percutaneous screw fixation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain management
Description: Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Non-operative management in the form of pain management and physical therapy advanced with weightbearing as tolerated
Study: NCT05312970

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varithena®
Description: Varithena® (polidocanol injectable foam) 1%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDA-approved Endothermal Ablation (ETA) systems
Description: FDA-approved ETA systems, including Radiofrequency ablation (RFA) systems or Endovenous laser ablation (EVLA) systems.
Study: NCT05284903

Intervention type: OTHER
Group type: OTHER
Intervention: Beamformer Benefit: Speech intelligibility and Listening effort
Description: Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.

Intervention type: OTHER
Group type: OTHER
Intervention: Beamformer Benefit: Speech intelligibility and Listening effort
Description: Confirm the improvement in terms of speech intelligibility (measured by OLSA, Oldenburg Sentence Test) and the reduction in terms of listening effort (measured by ACALES) of the I-BF (investigational Beamformer) compared to the R-BF (reference Beamformer), when speech is not coming from the front.

Intervention type: OTHER
Group type: OTHER
Intervention: Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility
Description: Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Speech Enhancer benefit: Speech intelligibility, Listening effort and Subjective Speech intelligibility
Description: Confirm the improvement in terms of speech intelligibility (measured by Oldenburg Sentence test) and the reduction in terms of listening effort (measured by ACALES) when the Speech Enhancer is on (SE ON) compared to Speech Enhancer is off (SE OFF) for distant speech or speech from adjacent room.~Confirm the improvement in terms of subjective level to follow a conversation in quiet when SE ON compared to SE OFF for distant speech or speech from adjacent room. Measured by a subjective assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)
Description: Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.
Study: NCT05163223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: On days 1-14 (Q3W), BID ; Oral administration,
Study: NCT04921618

Intervention type: OTHER
Intervention: 2 online self-administered questionnaires on
Description: 1. Participant profile~2. Spontaneous partner notification practices collected one month after STIs diagnosis

Intervention type: OTHER
Intervention: 2 online self-administered questionnaires on
Description: 1. Participant profile~2. Experiences with partner notification and use of STI testing following notification
Study: NCT06381167

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Decompressive Laminectomy
Description: the patients will undergo block randomization for either endoscopic or microscopic decompression

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Decompressive Laminectomy
Description: the patients will undergo block randomization for either endoscopic or microscopic decompression
Study: NCT05284903

Intervention type: OTHER
Group type: OTHER
Intervention: Hearing aid benefit: Speech intelligibility in noise (unaided vs aided condition)
Description: Confirm the improvement in terms of speech intelligibility (measured by OLSA) in noise with the investigational device (aided condition) compared to the unaided condition.

Intervention type: OTHER
Group type: OTHER
Intervention: Hearing aid benefit: Speech intelligibility in noise (aided condition)
Description: Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.

Intervention type: OTHER
Group type: OTHER
Intervention: Hearing aid benefit: Speech intelligibility in noise (aided condition)
Description: Confirm the improvement in terms of speech intelligibility (measured by OLSA) with the Reference binaural beamformer compared to the fixed directional.
Study: NCT04946526

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli seed extract
Description: 2 capsules, one dose

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccoli seed extract with mustard seed powder
Description: 2 capsules, one dose
Study: NCT04736095

Intervention type: DIAGNOSTIC_TEST
Intervention: 3D Ultrasound
Description: Doing 3D ultrasound for diagnosis of submucous myoma

Intervention type: DIAGNOSTIC_TEST
Intervention: Hysteroscopy
Description: Doing hysteroscopy for diagnosis of submucous myoma
Study: NCT05594329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant noodle soup containing containing the equivalent of 2 servings (18.78g) of powdered Pleurotus oyster mushroom.
Description: Ingredients: celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant noodle soup containing containing the equivalent of 1 serving (9.39g) of powdered Pleurotus oyster mushroom.
Description: Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instant noodle soup containing containing the equivalent of 0.5 serving (4.70g) of powdered Pleurotus oyster mushroom.
Description: Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, dried Pleurotus oyster mushroom, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control instant noodle soup
Description: Ingredients: cornflour, celery, garlic, ginger, gluten, polyphosphate, parsley, pepper, potassium carbonates, maltodextrin, salt, sodium, sunflower oil, turmeric, yeast extract and wheat flour.
Study: NCT05094180

Intervention type: OTHER
Group type: OTHER
Intervention: Face-to-face appointment
Description: Participants will be scheduled with face-to-face appointments as usual (control arm). All phone calls (except reminders for scheduled visits) performed by the physician during the study will be recorded. Per protocol, participants allocated in the control arm can receive up to 25% of physician-doctor interactions by phone (that is, one phone call allowed for three face-to-face appointments).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote consultation (telephone or video consultation mode)
Description: Patients will be seen through one of the two remote consultation modalities: video consultation or telephone. Patients will receive a reminder by text or call before the appointment.~In the case of telephone consultation, patients will be informed of the date and time slot in which they must wait for the doctor's call. At the time of the appointment, the doctor will call the contact phone number of the patients and/or their family members, starting with the first contact number that appears in the patient's medical history, and using the rest of the contacts available if there is no response. .~In the case of video consultation, at the time of the appointment, patients will receive a link to the application that manages the teleconsultation. Once in the application, they will remain in the virtual waiting room until the doctor switches to the videoconference.
Study: NCT06299735

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Cardiac Surgery (airway management with double-lumen tube)
Description: Anesthesia induction will involve 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. Following anesthesia induction, a double-lumen tube will be inserted.Subsequently, patients will be connected to a mechanical ventilator. Tube placement will be confirmed using fiberoptic bronchoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Minimally Invasive Cardiac Surgery (airway management with endobronchial blocker)
Description: Anesthesia induction will involve 1 mg/kg lidocaine, 1 µg/kg fentanyl, 1 mg/kg propofol, and 0.7 mg/kg rocuronium. Following anesthesia induction, endotracheal tube-bronchial blocker will be inserted.Subsequently, patients will be connected to a mechanical ventilator. Tube placement will be confirmed using fiberoptic bronchoscopy.
Study: NCT06308900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical simulation
Description: Carrying out a total of 9 clinical simulation in three days, one day a week, where the student resolves a situation by taking on the role of a physiotherapist with a simulated patient.